Bartlett & Co’s bluebird bio BLUE Stock Holding History

Bartlett & Co’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8	Closed	-$2K	–	460
2021 Q3	$2K	Buy	+8	New	+$2.29K	﹤0.01%	854

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bartlett & Co's BLUE Position: Q4 2021 in Review

Bartlett & Co sold out of bluebird bio (BLUE) in Q4 2021, closing a stake of 8 shares — an estimated $2K sold.

Bartlett & Co first reported a position in BLUE in Q3 2021 and held it in 1 quarter. The position peaked at $2K in Q3 2021. 172 funds tracked by Wall St. Rank hold BLUE as of Q4 2021.

Bartlett & Co reported no remaining bluebird bio position as of Q4 2021 after selling out during the quarter.
Bartlett & Co sold 8 bluebird bio shares in Q4 2021, an estimated $2K.
Bartlett & Co first reported a position in bluebird bio in Q3 2021 and held it in 1 quarter.
Bartlett & Co's bluebird bio position peaked at $2K in Q3 2021.
172 funds tracked by Wall St. Rank held bluebird bio as of Q4 2021.

Based on Bartlett & Co's 13F filing for Q4 2021, filed 8 Mar 2022.